Robert Mannel, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1568430007
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 37.8% of the total. Reporting peaked in 2023 at $244 and has fallen 89.7% since, to $25 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in OK, where the typical reported total is $3,072.
Across 11 payments — averaging $58.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$244
- Medtronic$189
- Portola Pharmaceuticals, LLC$125
- Genentech USA, Inc.$36
- GE HealthCare$29
- Astellas Pharma US Inc$22
- plus $1 from 1 others
Across 5 payments — averaging $1,156,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$5.8M
What the payments were for
- Food & beverage$646100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 3 | $244 |
| Medtronic | 2 | $189 |
| Portola Pharmaceuticals, LLC | 1 | $125 |
| Genentech USA, Inc. | 2 | $36 |
| GE HealthCare | 1 | $29 |
| Astellas Pharma US Inc | 1 | $22 |
| Clovis Oncology, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$125
- Reveal LINQ$105
How this compares
$647 in reported general payments places this provider in the 20th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 15 | $226,442 |
| ZejulaNiraparib Tosylate | 12 | $209,406 |
| Gabapentin | 18 | $252 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Oklahoma City
- Debra RichardsonOklahoma City$97K
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Elizabeth EvansOklahoma City$3K
- Lauren DockeryOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.